CN112273651A - Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof - Google Patents

Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof Download PDF

Info

Publication number
CN112273651A
CN112273651A CN202011234373.7A CN202011234373A CN112273651A CN 112273651 A CN112273651 A CN 112273651A CN 202011234373 A CN202011234373 A CN 202011234373A CN 112273651 A CN112273651 A CN 112273651A
Authority
CN
China
Prior art keywords
oil
dpa
dha
parts
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011234373.7A
Other languages
Chinese (zh)
Inventor
李媛媛
许团辉
陈璇
郑晓辉
王文谦
郑震堃
吴奕武
陈蝶玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Runke Bioengineering Fujian Co ltd
Original Assignee
Runke Bioengineering Fujian Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Runke Bioengineering Fujian Co ltd filed Critical Runke Bioengineering Fujian Co ltd
Priority to CN202011234373.7A priority Critical patent/CN112273651A/en
Publication of CN112273651A publication Critical patent/CN112273651A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

A soft capsule rich in microalgae oil DHA, DPA and EPA is characterized by comprising a capsule skin and contents, wherein the contents are wrapped by the capsule skin; the contents comprise 45-60 parts by weight of schizochytrium algae oil rich in DHA and DPA, 25-35 parts by weight of chlorella algae oil rich in EPA, 8-12 parts by weight of soybean lecithin, 3-10 parts by weight of edible oil and 2-4 parts by weight of vitamin E. The invention also provides a preparation method of the soft capsule rich in the microalgae oil DHA, DPA and EPA. The DHA, DPA, EPA, soybean lecithin and vitamin E in the soft capsule provided by the invention are mutually cooperated, so that the soft capsule can effectively prevent thick blood fat and cardiovascular and cerebrovascular diseases, and is convenient to store and eat.

Description

Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof
Technical Field
The invention relates to the technical field of soft capsules, and particularly relates to a soft capsule rich in microalgae oil DHA, DPA and EPA and a preparation method thereof.
Background
A large number of researches in recent years show that DHA and DPA, particularly DPA, have wide application prospects in reducing blood fat and preventing cardiovascular and cerebrovascular diseases.
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid, which is essential for human growth and health, can be synthesized in a small amount by human body but cannot meet the requirements of human body, needs to be taken from outside, is an important component of brain and eyes, and has important effect on the development of brain, vision and nerves of infants. However, DHA extracted from fish oil has a heavy fishy smell, has potential marine pollution hazards such as heavy metals and organic pollutants, and destroys the ecological balance of the sea due to a large amount of fish killing.
Docosapentaenoic acid (DPA) is widely present in fish oil such as tuna oil and salmon oil, marine mammal oil such as seal oil and seal oil, and is generally 1-5%, wherein seal oil and seal oil are higher in content, but seal and seal are national secondary protection animals, and are prohibited from being killed.
Eicosapentaenoic acid (EPA) is widely present in fish oils such as tuna oil, salmon oil, and the like, and at present, fish oil is a main source of EPA.
The DHA, DPA and EPA from the marine animals have certain limitations on sources and application, have the defects of exhaustion of marine resources, marine pollution, unstable sources and uncontrollable quality, and restrict the popularization and application of related products.
Disclosure of Invention
The invention aims to solve the technical problem of providing a soft capsule rich in microalgae oil DHA, DPA and EPA and a preparation method thereof, and the soft capsule can be used for preventing hyperlipidemia and cardiovascular and cerebrovascular diseases and is convenient to store and eat. The technical scheme is as follows:
a soft capsule rich in microalgae oil DHA, DPA and EPA is characterized by comprising a capsule skin and contents, wherein the contents are wrapped by the capsule skin; the contents comprise 45-60 parts by weight of schizochytrium algae oil rich in DHA and DPA, 25-35 parts by weight of chlorella algae oil rich in EPA, 8-12 parts by weight of soybean lecithin, 3-10 parts by weight of edible oil and 2-4 parts by weight of vitamin E.
The schizochytrium algae oil rich in DHA and DPA is liquid oil at normal temperature, the chlorella algae oil rich in EPA is also liquid oil at normal temperature, and because of containing a plurality of unsaturated bonds, the schizochytrium algae oil is extremely easy to oxidize in the air, generates lipid peroxide, is harmful to the body after being taken in a large amount, and generates unpleasant algae fishy smell at the same time, so the product form of the invention adopts a soft capsule, and the algae oil is wrapped by a capsule skin, thereby not only preventing the algae oil from being oxidized, ensuring the product quality, being beneficial to prolonging the quality guarantee period, but also being convenient to eat.
Research shows that DHA and DPA, especially DPA, have wide application prospects in reducing blood fat and preventing cardiovascular and cerebrovascular diseases. DPA can improve the content of high-density lipoprotein cholesterol, effectively reduce the risk of cardiovascular diseases, and has more obvious anti-inflammatory action compared with DHA and EPA.
Compared with fish oil DHA, DHA extracted from fish oil has heavier fishy smell and potential marine pollution hazards such as heavy metal, organic pollutants and the like, and marine ecological balance is damaged due to a large number of fishes being killed, while the microalgae DHA just overcomes the defects of the fish oil DHA, has the advantages of high growth rate, short culture period, high nutritional value, high biological accumulation amount, small occupied area and the like, and is safe and purely natural functional grease.
DHA can be used for preventing cardiovascular diseases, myocardial infarction, cerebral thrombosis and brain for adultsThe functions of improving the function of arteries, improving the autonomic regulation capability of the heart, reducing the occurrence of arrhythmia and the formation of atherosclerosis, preventing senile dementia and the like. Research shows that DHA can effectively inhibit the synthesis of cholesterol in vivo, can reduce low-density lipoprotein in blood and increase the content of high-density lipoprotein, changes the composition of lipoprotein in blood, can effectively promote the flow of blood, reduce blood pressure, and inhibit the formation of thrombus, thereby reducing the risk of cardiovascular and cerebrovascular diseases such as atherosclerosis. DHA can be added to Na in cardiac muscle cells＋-Ca２＋The converter is effectively adjusted, and the dynamic balance of the calcium ion channel can be effectively maintained; DHA may also have an antithrombotic effect through the production of prostaglandins on platelets and vessel walls. DHA is also a precursor of central nervous protective element, can promote the comprehensive metabolic activity of human brain and slow down the process of neurodegenerative diseases, and has effect of preventing senile dementia for the elderly.
Research finds that docosapentaenoic acid (DPA) has good anti-inflammatory effect, can reduce serum total cholesterol and non-high density lipoprotein cholesterol, and simultaneously DPA and DHA also have certain improvement effect on the function of aorta. DPA can reduce the content of triglyceride in blood fat, improve the content of high-density lipoprotein cholesterol, and effectively reduce the risk of cardiovascular diseases. Further research shows that DPA can reduce the expression level of mRNA of sterol regulation conjugated protein reductase-1 c, acetyl coenzyme A carboxylase-1 and fat synthetase in liver cells, can also reduce the expression of sterol regulation conjugated protein reductase-1 c and acetyl coenzyme A carboxylase-1 protein, and has the effects of promoting lipid metabolism and reducing lipid synthesis; the omega-3 PUFA has anti-inflammatory and immunoregulatory effects, DHA, DPA and EPA play positive roles in reducing the expression of inflammatory genes, DPA has more obvious anti-inflammatory effect, and the occurrence or development process of cardiovascular and cerebrovascular diseases is accompanied by acute or chronic inflammatory reaction, so the omega-3 PUFA has good effect of preventing cardiovascular and cerebrovascular diseases.
Eicosapentaenoic acid (EPA) has effects of improving blood circulation, softening blood vessel, regulating blood lipid, lowering blood pressure and blood sugar, and resisting inflammation. In the human body, EPA is mainly present in blood, has a significant effect of lowering cholesterol, triglycerides, very low density lipoproteins and low density lipoproteins in blood, and increases the content of high density lipoproteins and the fluidity of blood. EPA is precursor of eicosanoids such as prostaglandin I3 (PGI 3), thromboxane A3 (TXA 3), leukotriene B5 (LTB 5), and can inhibit platelet coagulation, inhibit thrombosis, and expand blood vessels, so EPA has important effects in preventing and treating cardiovascular and cerebrovascular diseases, anticancer, anti-inflammatory, and coronary heart disease. EPA also has effects in inhibiting synthesis of liver fat and lipoprotein, promoting cholesterol excretion, reducing triglyceride and low density cholesterol in blood, increasing beneficial high density cholesterol, preventing hyperlipidemia, inhibiting platelet aggregation, and reducing thrombosis. Meanwhile, the composition can expand blood vessels, reduce blood viscosity, increase red blood cell plasticity, improve platelet membrane fluidity, help maintain the smoothness of the blood vessels, and reduce the occurrence probability of atherosclerosis, thereby reducing the incidence of cardiovascular and cerebrovascular diseases.
The soybean lecithin can remove triglyceride in blood vessel wall, has very important effects on preventing and improving cardiovascular and cerebrovascular diseases, preventing fatty liver and liver cirrhosis, strengthening brain and improving intelligence, and can also enhance cell information transfer capability, improve brain activity and improve self-repairing capability of cell membrane.
The invention develops the soft capsule which can be used for reducing blood fat and preventing cardiovascular and cerebrovascular diseases by using DPA and DHA derived from schizochytrium oil and matching with EPA, soybean lecithin, vitamin E and the like derived from chlorella oil. In the soft capsule, DHA has the effects of reducing blood fat, regulating lipoprotein metabolism, and reducing blood viscosity and cholesterol level in blood; DPA has anti-inflammatory effect, and also has effects of reducing serum total cholesterol and non-high density lipoprotein cholesterol, and has good effect in preventing cardiovascular and cerebrovascular diseases; EPA has effects of improving blood circulation, softening blood vessel, regulating blood lipid, lowering blood pressure and blood sugar, and resisting inflammation; the soybean lecithin has the effects of removing triglyceride in the vascular wall, and has very important effects on preventing and improving cardiovascular and cerebrovascular diseases, preventing fatty liver and liver cirrhosis, and nourishing brain and improving intelligence; the Vitamin E (VE) is added, so that DHA, DPA and EPA can be kept from being oxidized, free radicals can be eliminated, and the oxidative damage to blood vessels can be avoided. The soft capsule can make DHA, DPA, EPA, soybean lecithin and vitamin E cooperate with each other, and effectively prevent blood lipid thickening and cardiovascular and cerebrovascular diseases.
The invention also provides a preparation method of the soft capsule rich in the microalgae oils DHA, DPA and EPA, which is characterized by comprising the following steps:
(1) preparing 45-60 parts by weight of schizochytrium limacinum algae oil rich in DHA and DPA, 25-35 parts by weight of chlorella oil rich in EPA, 8-12 parts by weight of soybean lecithin, 3-10 parts by weight of edible oil and 2-4 parts by weight of vitamin E, and then uniformly mixing the schizochytrium limacinum algae oil, the chlorella algae oil, the soybean lecithin, the edible oil and the vitamin E to obtain a content for later use;
(2) preparing 30-35 parts of edible gelatin, 10-15 parts of glycerol, 4-8 parts of trehalose, 2-4 parts of acetate starch, 2-4 parts of xylitol and 35-50 parts of purified water by weight; adding glycerol and purified water into a sol tank, heating to 65-75 deg.C, adding edible gelatin, acetic ester starch, trehalose, and xylitol, stirring for 20-30min, and vacuum defoaming to obtain capsule material;
(3) and pelleting, forming, washing and drying the prepared inclusion and capsule materials to prepare the soft capsule rich in the microalgae oil DHA, DPA and EPA.
Preferably, the weight ratio of the content to the capsule material in the step (3) is 1: 1.8-2.2.
And (4) after drying in the step (3), forming a capsule shell by using the capsule material, and wrapping the contents.
Trehalose is a seaweed polysaccharide substance extracted from seaweed such as kelp, is a natural colloid-forming material, has strong hydration and cohesiveness, and has the effects of regulating metabolism of a human body, preventing obesity, reducing blood sugar and blood pressure and the like.
Preferably, the content of DHA in the schizochytrium algae oil is 30-55 wt%, and the content of DPA in the schizochytrium algae oil is 15-20 wt%.
Preferably, the content of EPA in chlorella oil is 15-45 wt%.
Vegetable oil is usually used as the edible oil. Preferably, the edible oil is one or more of sunflower oil, walnut oil, linseed oil, grape seed oil, sesame oil, soybean oil and coconut oil.
The invention has the following beneficial effects:
in the soft capsule, DHA has the functions of reducing blood fat and regulating lipoprotein metabolism, and has the effects of reducing blood viscosity and cholesterol level in blood; DPA has anti-inflammatory effect, and also has effects of reducing serum total cholesterol and non-high density lipoprotein cholesterol, and has good effect in preventing cardiovascular and cerebrovascular diseases; EPA has effects of improving blood circulation, softening blood vessel, regulating blood lipid, lowering blood pressure and blood sugar, and resisting inflammation; the soybean lecithin has the effects of removing triglyceride in the vascular wall, and has very important effects on preventing and improving cardiovascular and cerebrovascular diseases, preventing fatty liver and liver cirrhosis, and nourishing brain and improving intelligence; the Vitamin E (VE) is added, so that DHA, DPA and EPA can be kept from being oxidized, free radicals can be eliminated, and the oxidative damage to blood vessels can be avoided. The soft capsule can make DHA, DPA, EPA, soybean lecithin and vitamin E cooperate with each other, and effectively prevent blood lipid thickening and cardiovascular and cerebrovascular diseases. The product in soft capsule form is convenient for storage and eating.
The main raw materials DHA, DPA and EPA of the inclusion of the invention are all from microalgae, are not harmed by potential marine pollution of heavy metals, organic pollutants and the like, and the damage to marine ecological balance caused by a large amount of fishes being killed is avoided. The DHA, DPA and EPA of the invention are derived from microalgae, the microalgae is easy to culture, the yield is stable, the invention can be industrially produced in a large scale, and the invention is green, pollution-free, controllable in quality and has wide application prospect.
Detailed Description
The detection of DHA, DPA and EPA contents refers to GB/T38095-.
Example 1
In this embodiment, the preparation method of the soft capsule rich in the microalgae oils DHA, DPA and EPA includes the following steps:
(1) preparing 45 parts by weight of schizochytrium algae oil rich in DHA and DPA (the DHA content of the schizochytrium algae oil is about 50% by weight, and the DPA content of the chlorella algae oil is about 18%) and 30 parts by weight of EPA-rich chlorella algae oil (the EPA content of the chlorella algae oil is about 30%), 12 parts by weight of soybean lecithin, 10 parts by weight of edible oil (both sunflower seed oil) and 3 parts by weight of vitamin E, and then uniformly mixing the schizochytrium algae oil, the chlorella algae oil, the soybean lecithin, the edible oil;
(2) preparing 33 parts of edible gelatin, 13 parts of glycerol, 4 parts of trehalose, 3 parts of acetate starch, 3 parts of xylitol and 44 parts of purified water by weight; adding glycerol and purified water into a sol tank, heating to 72 ℃, adding edible gelatin, acetic ester starch, trehalose and xylitol, continuously stirring for 30min, and performing vacuum deaeration to obtain a capsule material;
(3) and pelleting, forming, washing and drying the prepared inclusion and capsule materials to prepare the soft capsule rich in the microalgae oil DHA, DPA and EPA.
In the step (3), the weight ratio of the inclusion and the capsule material is 1: 2.
the prepared soft capsule rich in microalgae oil DHA, DPA and EPA comprises a capsule skin and contents, wherein the contents are wrapped by the capsule skin; the contents comprise 45 parts of schizochytrium algae oil rich in DHA and DPA, 30 parts of chlorella algae oil rich in EPA, 12 parts of soybean lecithin, 10 parts of edible oil and 3 parts of vitamin E by weight.
The content of the soft capsule prepared in this example was examined, wherein the content of DHA was 22.32 wt%, the content of DPA was 8.04 wt%, and the content of EPA was 8.93 wt%.
Example 2
In this embodiment, the preparation method of the soft capsule rich in the microalgae oils DHA, DPA and EPA includes the following steps:
(1) preparing 50 parts by weight of schizochytrium algae oil rich in DHA and DPA (the weight percentage content of DHA in the schizochytrium algae oil is about 53.6 percent, the weight percentage content of DPA is about 19.7 percent), 35 parts by weight of chlorella algae oil rich in EPA (the weight percentage content of EPA in the chlorella algae oil is about 31 percent), 9 parts by weight of soybean lecithin, 3 parts by weight of edible oil (1 part by weight of sunflower seed oil and 2 parts by weight of walnut oil) and 3 parts by weight of vitamin E, and then uniformly mixing the schizochytrium algae oil, the chlorella algae oil, the soybean lecithin, the edible oil and the vitamin E to obtain a content for later use;
(2) preparing 30 parts of edible gelatin, 15 parts of glycerol, 7 parts of trehalose, 2 parts of acetate starch, 3 parts of xylitol and 43 parts of purified water by weight; adding glycerol and purified water into a sol tank, heating to 72 ℃, adding edible gelatin, acetic ester starch, trehalose and xylitol, continuously stirring for 30min, and performing vacuum deaeration to obtain a capsule material;
(3) and pelleting, forming, washing and drying the prepared inclusion and capsule materials to prepare the soft capsule rich in the microalgae oil DHA, DPA and EPA.
In the step (3), the weight ratio of the inclusion and the capsule material is 1: 1.8.
the prepared soft capsule rich in microalgae oil DHA, DPA and EPA comprises a capsule skin and contents, wherein the contents are wrapped by the capsule skin; the contents comprise 50 parts of schizochytrium algae oil rich in DHA and DPA, 35 parts of chlorella algae oil rich in EPA, 9 parts of soybean lecithin, 3 parts of edible oil and 3 parts of vitamin E by weight.
The content of the soft capsule prepared in this example was examined, wherein the content of DHA was 26.79 wt%, the content of DPA was 9.82 wt%, and the content of EPA was 10.71 wt%.
Example 3
In this embodiment, the preparation method of the soft capsule rich in the microalgae oils DHA, DPA and EPA includes the following steps:
(1) preparing 56 parts by weight of schizochytrium algae oil rich in DHA and DPA (the weight percentage content of DHA in the schizochytrium algae oil is about 51.5 percent, the weight percentage content of DPA is about 19.2 percent), 28 parts by weight of chlorella algae oil rich in EPA (the weight percentage content of EPA in the chlorella algae oil is about 38.5 percent), 10 parts by weight of soybean lecithin, 3 parts by weight of edible oil (both sunflower seed oil) and 3 parts by weight of vitamin E, and then uniformly mixing the schizochytrium algae oil, the chlorella algae oil, the soybean lecithin, the edible oil and the vitamin E to obtain a content for later use;
(2) preparing 30 parts of edible gelatin, 13 parts of glycerol, 4 parts of trehalose, 2 parts of acetate starch, 3 parts of xylitol and 48 parts of purified water by weight; adding glycerol and purified water into a sol tank, heating to 70 deg.C, adding edible gelatin, acetic ester starch, trehalose, and xylitol, stirring for 25min, and vacuum defoaming to obtain capsule material;
(3) and pelleting, forming, washing and drying the prepared inclusion and capsule materials to prepare the soft capsule rich in the microalgae oil DHA, DPA and EPA.
The prepared soft capsule rich in microalgae oil DHA, DPA and EPA comprises a capsule skin and contents, wherein the contents are wrapped by the capsule skin; the contents comprise, by weight, 56 parts of schizochytrium algae oil rich in DHA and DPA, 28 parts of chlorella algae oil rich in EPA, 10 parts of soybean lecithin, 3 parts of edible oil and 3 parts of vitamin E.
In the step (3), the weight ratio of the inclusion and the capsule material is 1: 2.1.
the content of the soft capsule prepared in this example was measured, wherein the content of DHA was 28.57 wt%, the content of DPA was 10.71 wt%, and the content of EPA was 10.71 wt%.
Example 4 stability test validation
The soft capsules rich in the microalgae oils DHA, DPA and EPA in examples 1, 2 and 3 of the invention are subjected to an accelerated test for 3 months at 40 ℃ and 75% of relative humidity, the content of DHA, DPA and EPA in the capsule content is detected in 1 month, 2 months and 3 months respectively, and comparative statistics is carried out with the initial detection value as 100%. The stability test results are shown in table 1 below.
TABLE 1 stability test of soft capsules enriched in the microalgae oils DHA, DPA and EPA
Figure DEST_PATH_IMAGE002
Example 5 taste test
The soft capsules rich in the microalgae oils DHA, DPA and EPA of examples 1, 2 and 3 of the present invention were subjected to an accelerated test for 3 months at 40 ℃ and a relative humidity of 75%. Samples were tasted at 0 months (prepared or cryopreserved) and 3 months accelerated. Forming a sensory evaluation panel, and evaluating the color and taste of the soft capsules 0d and 90d rich in the microalgae oil DHA, DPA and EPA. Character evaluation standard: soft, yellow with 0 point of luster; soft, yellow and dull by 1 point; hardening, no luster for 2 points; harder, darker color by 3 minutes; hard, dark 4 minutes; harder, 5 points of leakage. Judgment standard of algae fishy smell: no algae fishy smell is 0, very light microalgae fishy smell is 1, slight algae fishy smell is 2, medium algae fishy smell is 3, heavy algae fishy smell is 4 and heavy algae fishy smell is 5. The evaluation results are shown in table 2.
TABLE 2
Figure DEST_PATH_IMAGE004
Example 6 functional verification of Soft capsules enriched in microalgae oils DHA, DPA and EPA
This example 6 is a functional verification of the soft capsule rich in DHA, DPA and EPA for preventing blood lipid thickening and cardiovascular and cerebrovascular diseases.
Experimental materials: the soft capsule rich in the microalgae oils DHA, DPA and EPA prepared in example 2.
First, animal experiment
Experimental animals: healthy adult SD rats, male, clean grade, body weight (180 ± 20 g).
The name of the inspection institution: beijing Union university applies the research institute health food function testing center.
The inspection basis is as follows: the national food and drug administration document [2012]107 assists the evaluation method of the function of reducing blood fat.
The purpose is as follows: determining the auxiliary blood fat reducing and health care functions of the soft capsule rich in the microalgae oil DHA, DPA and EPA.
The inspection acceptance number is: GZ02720150054
And (4) checking items: auxiliary hypolipidemic function (animal test)
Dosage: the specification of the product is 0.8 g/grain, 1 grain per day. The recommended daily intake of the human body is 800mg/60kg & BW (0.013 g/kg & BW), and experiments show that the recommended daily intake of the human body is 2.5, 5 and 15 times, namely 0.033g/kg & BW, 0.067g/kg & BW and 0.2g/kg & BW are low, medium and high dose groups per day.
The experimental method comprises the following steps: 60 male SD rats of SPF-class wistar are adopted, wherein 12 rats are given maintenance feed as a blank control group, 48 rats are given high-fat feed as a model group, after the model group is given the high-fat feed for 14 days, the rats of the blank control group and the model group are not fasted for blood taking, and serum is centrifugally separated after the blood taking for measuring the serum total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. The model groups were randomized into four groups according to total cholesterol levels: model control group, low dose group, medium dose group, high dose group. A mixed hyperlipidemia animal model experimental method is adopted, and DHA algae oil lipid-lowering soft capsules with different doses are orally administered to hyperlipidemia model rats for 32 d.
As a result:
(1) compared with model control group, the test substance in middle dose group can reduce total cholesterol content (P < 0.05) in serum of rat with hyperlipemia model, and reduce serum triglyceride content (P < 0.01);
(2) compared with model control group, the test substance can reduce total cholesterol content (P < 0.001), serum triglyceride content (P < 0.05), and serum low density lipoprotein cholesterol (P < 0.01) in high-dose group of rat with hyperlipemia;
(3) the test substance has no influence on serum high-density lipoprotein cholesterol of rats in each dose group, and has no adverse effect on weight gain of the rats.
According to annex 6 of national food and drug administration [2012] 107: according to the judgment standard of the auxiliary blood fat reducing function evaluation method, the soft capsule rich in the microalgae oil DHA, DPA and EPA has a positive auxiliary blood fat reducing function animal test result.
Second, human body test
The name of the inspection institution: beijing Union university applies the research institute health food function testing center.
The inspection basis is as follows: the national food and drug administration document [2012]107 assists the evaluation method of the function of reducing blood fat.
The purpose is as follows: determining the auxiliary blood fat reducing and health care functions of the soft capsule rich in the microalgae oil DHA, DPA and EPA.
The inspection acceptance number is: GZ 02720150054.
And (4) checking items: human body test eating test with auxiliary blood fat reducing function.
Experimental design and grouping: two control designs, self and group, were used. And grouping according to the requirement of a random blind method. The test group and the control group are randomly divided according to the blood lipid level of a subject, and main factors influencing the result, such as age, sex, diet and the like, are considered as much as possible to carry out balance test so as to ensure comparability among the groups. Not less than 50 subjects per group. The test group takes the test sample, and the control group adopts blank control.
The edible dosage and the edible time are as follows: the subjects maintained their usual life and eating habits during the test period. The test group takes the sample 1 time a day, 1 granule each time, orally, and continuously takes for 90 days. Blank control was used for the control group.
And (4) testing results: two control designs between self and group were used. 103 effective hyperlipoidemia subjects meeting the requirements, 52 test-diet groups and 51 control groups. The life and eating habits are kept in a normal day during the test period, no adverse reaction is caused after the test period of taking the test food for 90 days, and the main clinical symptoms are improved. The serum total cholesterol, triglyceride and high density lipoprotein cholesterol between the two groups before the test eating have no obvious difference and are comparable; compared with the blood serum total cholesterol before and after the test of the test group, the blood serum total cholesterol is averagely reduced (0.89 +/-0.44) mmol/L (P is less than 0.001), the average reduction percentage is 15.93 percent, and the effective rate is 78.8 percent; the average reduction (0.66 +/-0.35) mmol/L (P is less than 0.001) of the serum triglyceride, the average reduction percentage is 35.54 percent, and the effective rate is 84.6 percent; the serum low density lipoprotein cholesterol is reduced (P is less than 0.001), and the content difference of the serum high density lipoprotein cholesterol is not significant (P is more than 0.05). In 52 cases of the test group, the total effective rate is 51.9 percent and is obviously higher than that of a control group (P is less than 0.001) in 27 cases of the total effective rate. Compared with the control group, the test group after test feeding has reduced serum total cholesterol (P < 0.001), reduced serum triglyceride (P < 0.001), lower serum low density lipoprotein cholesterol (P < 0.05), and no significant difference in serum high density lipoprotein cholesterol (P > 0.05). The indexes of blood convention, urine convention, stool convention and blood biochemistry (except blood fat) before and after the test eating of the test eater are in normal ranges, which shows that the product has no adverse effect on the body health of the test eater; no allergic or other adverse reactions were observed during the test feeding.
According to the judgment standard of human body feeding trial test with the function of assisting blood fat reduction of accessory 6 in the national food supervision and administration (State food and drug administration [2012] 107), the result shows that the soft capsule rich in the microalgae oil DHA, DPA and EPA has the function of assisting blood fat reduction.

Claims (9)

1. A soft capsule rich in microalgae oil DHA, DPA and EPA is characterized by comprising a capsule skin and contents, wherein the contents are wrapped by the capsule skin; the contents comprise 45-60 parts by weight of schizochytrium algae oil rich in DHA and DPA, 25-35 parts by weight of chlorella algae oil rich in EPA, 8-12 parts by weight of soybean lecithin, 3-10 parts by weight of edible oil and 2-4 parts by weight of vitamin E.
2. The soft capsule enriched in microalgae oils DHA, DPA and EPA according to claim 1, characterized by: the content of DHA in the schizochytrium limacinum algae oil is 30-55 wt%, and the content of DPA in the schizochytrium limacinum algae oil is 15-20 wt%.
3. The soft capsule enriched in microalgae oils DHA, DPA and EPA according to claim 1, characterized by: the chlorella algae oil contains 15-45 wt% of EPA.
4. The soft capsule enriched in microalgae oils DHA, DPA and EPA according to claim 1, characterized by: the edible oil is one or more of sunflower seed oil, walnut oil, linseed oil, grape seed oil, sesame oil, soybean oil and coconut oil.
5. The process for the preparation of soft capsules enriched in the microalgae oils DHA, DPA and EPA according to claim 1, characterized by comprising the following steps:
(1) preparing 45-60 parts by weight of schizochytrium limacinum algae oil rich in DHA and DPA, 25-35 parts by weight of chlorella oil rich in EPA, 8-12 parts by weight of soybean lecithin, 3-10 parts by weight of edible oil and 2-4 parts by weight of vitamin E, and then uniformly mixing the schizochytrium limacinum algae oil, the chlorella algae oil, the soybean lecithin, the edible oil and the vitamin E to obtain a content for later use;
(2) preparing 30-35 parts of edible gelatin, 10-15 parts of glycerol, 4-8 parts of trehalose, 2-4 parts of acetate starch, 2-4 parts of xylitol and 35-50 parts of purified water by weight; adding glycerol and purified water into a sol tank, heating to 65-75 deg.C, adding edible gelatin, acetic ester starch, trehalose, and xylitol, stirring for 20-30min, and vacuum defoaming to obtain capsule material;
(3) and pelleting, forming, washing and drying the prepared inclusion and capsule materials to prepare the soft capsule rich in the microalgae oil DHA, DPA and EPA.
6. The method for preparing soft capsules enriched in microalgae oils DHA, DPA and EPA according to claim 5, characterized in that: the content of DHA in the schizochytrium limacinum algae oil is 30-55 wt%, and the content of DPA in the schizochytrium limacinum algae oil is 15-20 wt%.
7. The method for preparing soft capsules enriched in microalgae oils DHA, DPA and EPA according to claim 5, characterized in that: the chlorella algae oil contains 15-45 wt% of EPA.
8. The method for preparing soft capsules enriched in microalgae oils DHA, DPA and EPA according to claim 5, characterized in that: the edible oil is one or more of sunflower seed oil, walnut oil, linseed oil, grape seed oil, sesame oil, soybean oil and coconut oil.
9. The method for preparing soft capsules enriched in microalgae oils DHA, DPA and EPA according to claim 5, characterized in that: in the step (3), the weight ratio of the inclusion and the capsule material is 1: 1.8-2.2.
CN202011234373.7A 2020-11-07 2020-11-07 Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof Pending CN112273651A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011234373.7A CN112273651A (en) 2020-11-07 2020-11-07 Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011234373.7A CN112273651A (en) 2020-11-07 2020-11-07 Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof

Publications (1)

Publication Number Publication Date
CN112273651A true CN112273651A (en) 2021-01-29

Family

ID=74350439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011234373.7A Pending CN112273651A (en) 2020-11-07 2020-11-07 Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112273651A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113951508A (en) * 2021-12-06 2022-01-21 武汉酷尔生物科技有限公司 Food composition for reducing high blood pressure, high blood sugar and high blood fat
CN114146026A (en) * 2021-12-14 2022-03-08 上海家化联合股份有限公司 Compositions comprising microbial oils and uses thereof
FR3132430A1 (en) * 2022-02-09 2023-08-11 Polaris COMPOSITION COMPRISING A MIXTURE OF DHA AND/OR EPA AND A PHOSPHOLIPIDE OF PLANT ORGINE

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104522649A (en) * 2014-12-18 2015-04-22 润科生物工程（福建）有限公司 Perilla seed oil and DHA (docosahexenoic acid) algal oil containing soft capsule and preparation method thereof
CN105287430A (en) * 2015-12-01 2016-02-03 广州市富诺生物科技有限公司 Algae oil soft capsule and preparation method thereof
CN106136243A (en) * 2016-08-26 2016-11-23 李仁宝 A kind of Sargassum extract health care soft capsule
CN106617076A (en) * 2016-09-30 2017-05-10 广州康琪莱生物科技有限公司 Composition for assisting in reducing blood lipid, preparation method of composition, and health-care food including composition
US20170151296A1 (en) * 2015-12-01 2017-06-01 Infinitus (China) Company Ltd. Composition and use thereof
CN107596019A (en) * 2017-10-20 2018-01-19 吉林省世龙药业集团有限公司 A kind of Seabuckthorm Seed Oil soft capsule and preparation method thereof
CN109938147A (en) * 2019-03-29 2019-06-28 江西美好时光生物科技有限公司 A kind of low sugar DHA gel candy improving memory and strengthen immunity
CN111388442A (en) * 2020-03-24 2020-07-10 广州普正生物科技有限公司 Gel candy type plant soft capsule

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104522649A (en) * 2014-12-18 2015-04-22 润科生物工程（福建）有限公司 Perilla seed oil and DHA (docosahexenoic acid) algal oil containing soft capsule and preparation method thereof
CN105287430A (en) * 2015-12-01 2016-02-03 广州市富诺生物科技有限公司 Algae oil soft capsule and preparation method thereof
US20170151296A1 (en) * 2015-12-01 2017-06-01 Infinitus (China) Company Ltd. Composition and use thereof
CN106136243A (en) * 2016-08-26 2016-11-23 李仁宝 A kind of Sargassum extract health care soft capsule
CN106617076A (en) * 2016-09-30 2017-05-10 广州康琪莱生物科技有限公司 Composition for assisting in reducing blood lipid, preparation method of composition, and health-care food including composition
CN107596019A (en) * 2017-10-20 2018-01-19 吉林省世龙药业集团有限公司 A kind of Seabuckthorm Seed Oil soft capsule and preparation method thereof
CN109938147A (en) * 2019-03-29 2019-06-28 江西美好时光生物科技有限公司 A kind of low sugar DHA gel candy improving memory and strengthen immunity
CN111388442A (en) * 2020-03-24 2020-07-10 广州普正生物科技有限公司 Gel candy type plant soft capsule

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
常桂芳等: "通过商品化DHA藻油的脂肪酸组成推测其微藻属名", 《中国油脂》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113951508A (en) * 2021-12-06 2022-01-21 武汉酷尔生物科技有限公司 Food composition for reducing high blood pressure, high blood sugar and high blood fat
CN114146026A (en) * 2021-12-14 2022-03-08 上海家化联合股份有限公司 Compositions comprising microbial oils and uses thereof
FR3132430A1 (en) * 2022-02-09 2023-08-11 Polaris COMPOSITION COMPRISING A MIXTURE OF DHA AND/OR EPA AND A PHOSPHOLIPIDE OF PLANT ORGINE
WO2023152122A1 (en) * 2022-02-09 2023-08-17 Polaris Composition comprising a mixture of dha and/or epa and a plant-derived phospholipid

Similar Documents

Publication Publication Date Title
US20200078464A1 (en) Polyunsaturated fatty acid-containing solid fat compositions and uses and production thereof
KR100423013B1 (en) Utilization of material containing docosapentaenoic acid
EP0568608B1 (en) Fungal oil containing arachidonic acid, method for its preparation and composition containing said oil
AU2006265801B2 (en) Polyunsaturated fatty acid-containing oil product and uses and production thereof
EP0800584B1 (en) Arachidonic acid and methods for the production and use thereof
CN112273651A (en) Soft capsule rich in microalgae oil DHA, DPA and EPA and preparation method thereof
KR101362989B1 (en) Lipid-improving agent and composition containing lipid-improving agent
JP2008133286A (en) Useful method and pharmaceutical composition for treatment of neurological disorder
CN105925627B (en) Microbial oil and preparation method thereof
WO2020244315A1 (en) Glyceride mixture rich in polyunsaturated fatty acids, preparation method therefor and application thereof
JPWO2019208803A1 (en) Microbial oil and method for producing microbial oil
JP2022500049A (en) Extraction method of oil rich in polyunsaturated fatty acid (PUFA)
CN110235960B (en) Preparation and application of olive oil derivative rich in balanced unsaturated fatty acid
CN105713936B (en) The preparation method of microbial oil
WO2023145785A1 (en) Thrombosis preventive agent
Bhosale et al. Freshwater algae as potential source of polyunsaturated fatty acids
AU2015200426A1 (en) Polyunsaturated fatty acid-containing solid fat compositions and uses and production thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination